The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 07, 2021
Filed:
Nov. 15, 2019
Applicant:
Acadia Pharmaceuticals Inc., San Diego, CA (US);
Inventor:
Andrew Parkinson, Shawnee, KS (US);
Assignee:
ACADIA Pharmaceuticals Inc., San Diego, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/4468 (2006.01); A61K 31/496 (2006.01); A61K 31/7048 (2006.01); A61K 9/00 (2006.01); A61P 25/18 (2006.01); A61P 25/24 (2006.01); A61K 45/06 (2006.01); A61P 25/28 (2006.01); A61P 25/16 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4468 (2013.01); A61K 9/00 (2013.01); A61K 45/06 (2013.01); A61P 25/16 (2018.01); A61P 25/18 (2018.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01); A61K 31/496 (2013.01); A61K 31/7048 (2013.01);
Abstract
A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.